{"changeSha256":"ebdaaec1331aee1b79f57d9911fc95cd99bf1aa9769fc548bdc16292e1af2b6e","changedAt":"2026-11-15","changedFields":[{"after":"A GnRH agonist FDA-approved since 1985 under several names. The cited Eligard label covers advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.","before":"A GnRH agonist FDA-approved since 1985 under several names. The cited label covers palliative treatment of advanced prostate cancer; FDA approved Vobrig for central precocious puberty in August 2026.","field":"Profile summary"},{"after":"The cited Eligard label describes four open-label studies that measured testosterone suppression in men with prostate cancer. Each leuprolide product has its own label and uses.","before":"The label describes a controlled comparison with another hormone treatment in prostate cancer, and leuprolide served as the comparison treatment in a large randomized trial. Each leuprolide product has its own label and uses.","field":"Evidence note"},{"after":"dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183, fda-drugs-nda213225-2026-08-26-94e1fef9b739","before":"dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda020263-1993-04-16-d5ec3f5822e0, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-drugs-nda213150-2020-05-01-40513bba6c48, fda-vobrig-approval-2026, journal-pmid-32469183","field":"Cited source records"},{"after":"U.S. National Library of Medicine [sources: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]","before":"U.S. National Library of Medicine [sources: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10]; U.S. Food and Drug Administration [sources: fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026]","field":"Named organizations"},{"after":"name: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19; aliases: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19; status: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026, fda-drugs-nda213225-2026-08-26-94e1fef9b739; summary: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19","before":"name: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; aliases: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; category: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10; status: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-drugs-nda019732-1989-01-26-f4233297ff5a, fda-drugs-nda021343-2002-01-23-f17a5edda965, fda-vobrig-approval-2026; summary: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, fda-drugs-nda019010-1985-04-09-d97355079c93, fda-vobrig-approval-2026; evidenceNote: dailymed-leuprolide-4838c674-044e-46b2-81e7-c691b99d8fa5-v10, journal-pmid-32469183","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/leuprolide/versions/4/","version":4},"id":"profile:leuprolide:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We re-based this profile on the current Eligard label on DailyMed (SPL version 19, published May 11, 2026), because the generic label cited before is no longer marketed or served, and now describe the studies that label reports. HERO is described only as a trial in which leuprolide was the comparison treatment. Earlier versions remain available.","peptideSlugs":["leuprolide"],"previousChangeEvent":{"path":"/corrections/v1/profiles/leuprolide/v3.json","sha256":"8095af238057e54392fc9776cac7e48f99cae7da97d092040490f56fa014c2f6"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/leuprolide/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"dailymed-leuprolide-b7b679a9-6823-4ef8-8d31-3ab5058ffcfc-v19","name":"DailyMed · U.S. National Library of Medicine","sourceClass":"A","title":"ELIGARD (leuprolide acetate) injection, suspension, extended release · SPL version 19 · published 2026-05-11","url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?type=zip&setid=b7b679a9-6823-4ef8-8d31-3ab5058ffcfc&version=19","verifiedAt":"2026-11-15"},{"id":"fda-drugs-nda021343-2002-01-23-f17a5edda965","name":"Drugs@FDA via openFDA","sourceClass":"A","title":"Drugs@FDA application NDA021343 · original submission status AP · 2002-01-23 · dataset 2026-08-13","url":"https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA021343%22&limit=1","verifiedAt":"2026-08-14"}],"subject":{"slug":"leuprolide","type":"profile"}}
